Elimination of Antiestrogenic Effects of Active Tamoxifen Metabolites by Glucuronidation
Authors:
- Dongxiao SunDSDongxiao Sun
- Arun K. SharmaArun K. Sharma
- Gang ChenGCGang Chen
- Shantu AminSAShantu Amin
- Philip LazarusPLPhilip Lazarus
- 1 October 2007
- journal article
- Published by Elsevier in Drug Metabolism and Disposition
- Vol. 35 (10) , 1942-1948
Abstract
1-[4-(2-Dimethylaminoethoxy)-phenyl]-1,2-diphenylbut-1-(Z)-ene (tamoxifen, TAM) is a nonsteroidal antiestrogen that has been commonly used for the prevention and treatment of estrogen receptor-positive breast cancer. TAM is extensively metabolized into several primary active metabolites including 4-hydroxy-TAM (4-OH-TAM) and endoxifen. Glucuronidation is the major phase II metabolic pathway important in their excretion. Whereas high antiestrogenic activity has been reported for both 4-OH-TAM and endoxifen, studies examining the effect of glucuronide conjugation of these metabolites have not previously been performed. In the present study, the antiestrogenic activities of glucuronidated TAM metabolites were determined by examining their effect on the induction of the estrogen-responsive progesterone receptor (PGR) gene. 17β-Estradiol (E2)-mediated PGR gene expression in MCF-7 cells was determined by real-time reverse transcriptase-polymerase chain reaction for each TAM metabolite isomer. E2 (1 × 10-10 M) induction of PGR mRNA was 6-fold after a 12-h incubation; only unconjugated TAM metabolites inhibited this effect. A virtually identical dose-dependent inhibition of E2-induced PGR gene expression was found for both the trans- and cis-isomers of 4-OH-TAM and endoxifen, with maximal inhibition attained at 1 × 10-6 M of TAM metabolite. The glucuronide conjugates of all 4-OH-TAM and endoxifen isomers exhibited no effect on E2-mediated induction of PGR expression at all concentrations of TAM metabolite examined in this study. These data indicate that isomers of both 4-OH-TAM and endoxifen exhibit roughly equipotent antiestrogenic effects on E2-induced gene expression and that glucuronide conjugates of the same metabolites effectively negate this activity. This result may have important implications in terms of both whole-body and target tissue-specific glucuronidation pathways and individual responses to TAM therapy and cancer prevention.Keywords
This publication has 33 references indexed in Scilit:
- Comprehensive Evaluation of Tamoxifen Sequential Biotransformation by the Human Cytochrome P450 System in Vitro: Prominent Roles for CYP3A and CYP2D6The Journal of Pharmacology and Experimental Therapeutics, 2004
- Correlation between the UDP-Glucuronosyltransferase (UGT1A1) TATAA Box Polymorphism and Carcinogen Detoxification PhenotypeCancer Epidemiology, Biomarkers & Prevention, 2004
- Oxidative metabolism of tamoxifen to Z‐4‐hydroxy‐tamoxifen by cytochrome P450 isoforms: An appraisal of in vitro studiesClinical and Experimental Pharmacology and Physiology, 2003
- Overview of the main outcomes in breast-cancer prevention trialsThe Lancet, 2003
- Metabolism of Tamoxifen by Recombinant Human Cytochrome P450 Enzymes: Formation of the 4-Hydroxy, 4′-Hydroxy and N-Desmethyl Metabolites and Isomerization of trans-4-HydroxytamoxifenDrug Metabolism and Disposition, 2002
- The influence of CYP2B6, CYP2C9 and CYP2D6 genotypes on the formation of the potent antioestrogen Z‐4‐hydroxy‐tamoxifen in human liverBritish Journal of Clinical Pharmacology, 2002
- Tamoxifen for Prevention of Breast Cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 StudyJNCI: Journal of the National Cancer Institute, 1998
- Tamoxifen for early breast cancer: an overview of the randomised trialsThe Lancet, 1998
- Variable contribution of cytochromes p450 2d6, 2c9 and 3a4 to the 4-hydroxylation of tamoxifen by human liver microsomesBiochemical Pharmacology, 1997
- EVIDENCE FOR THE METABOLIC ACTIVATION OF NON‐STEROIDAL ANTIOESTROGENS: A STUDY OF STRUCTURE‐ACTIVITY RELATIONSHIPSBritish Journal of Pharmacology, 1980